19-Oct-2021 | Market Research Store
Placenta accreta spectrum (PAS), also referred to as morbidly adherent placenta, is a perilous condition, during whichthe placenta is unable to detach naturally from the uterus of the mother after delivery. The attached placenta has to be removed through clinical procedures, which could be life-threatening and might cause severe hemorrhage-like issues. The possible rate of occurrence of PAS is 1 in 500 pregnant women, which is rising worldwide due to burgeoning cases of cesarean delivery.
For the early diagnosis of PASduring the initial phases of fertility,one needs a precise and sensitive tool to assist the clinical team in managing the issue more effectively. At present, an international team of scientists from Cedars-Sinai and University of California, Los Angeles hasdesignedNanoVelcro Chip—a non-invasive device for entrapping cells, which focuses on early & quick detection of PAS. The research findings and overview of the novel device are available in a research article recently published in the journal Nature Communications.
Yalda Afshar,the first co-author of the research and the scientist at UCLA, stated that the precise and swift detection of such obstetrical emergencies can significantly enhance results for both infant and mother. Since uncertainty is associated with the existing screening approaches for placenta accreta, it seems mandatory to develop anovel screening approach, which can beeasily implemented during the initial stages of pregnancy irrespective of the resources.
After adhering to the uterine lining, the trophoblast cells provide nutrition to the placenta during the normal pregnancy. Later, these placental trophoblasts detach from the wall of the uterus and enter the maternal bloodstream. During this process, a mishappeningmaytake place, which causes an unusually large number of trophoblasts to adhere to the uterine lining.After which many trophoblasts started circulating within the bloodstream of a pregnant mother.
The NanoVelcro Chip is equippedwith a device that bifurcates the blood sample in the two functional elements of the microchip.To determine how efficient this novel microchip is, the researchers employed the NanoVelcro device to analyze the blood samples collected from 183 females, of which 168 were pregnant who were diagnosed with PAS disorder and 15 were healthy non-pregnant females.The outcomes of this preliminary study demonstrated that the numberof trophoblasts circulating in the pregnant women suffering from PAS were significantly higher than in the healthy control group females.